Press Releases

and/or
568 News Releases found
Memorial Sloan Kettering shares results of a recent review by our Boards of Overseers and Managers, as well as additional policies we are considering to enhance communication, transparency, disclosure, and oversight of outside activities and industry-supported clinical trials.
Memorial Sloan Kettering and Paige.AI
MSK was recently in the news regarding our relationship with a technology spin-off company called Paige.AI.
Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials.
The Ralph Lauren Center for Cancer Care, a Harlem-based cancer prevention and treatment program, is expected to more closely align with Memorial Sloan Kettering Cancer Center (MSK) in 2019 pending the approval of the New York State Department of Health and other state agencies. The filing deepens the longstanding partnership between MSK and the Ralph Lauren Center. 
Kenneth Manotti, Senior Vice President and Chief Development Officer at MSK
Kenneth Manotti has been named Senior Vice President and Chief Development Officer at Memorial Sloan Kettering Cancer Center (MSK).
 J. Ted Gerstle
Pediatric surgeon J. Ted Gerstle, MD, FACS, FRCS, has been named the new Chief of the Pediatric Surgery Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK).
Memorial Sloan Kettering Cancer Center (MSK) has announced that Kreg Koford has been named MSK's Senior Vice President of Supply Chain and Sustaining Care Services. Mr. Koford assumes his new role at MSK on July 9, 2018.
After more than two decades of providing outstanding cancer care to the people of New Jersey, Memorial Sloan Kettering announced today that its newest outpatient treatment center, in Bergen County, will welcome new patients in the coming weeks. In recognition of its debut, MSK’s leadership, joined by members of the community and local elected officials, gathered at the Montvale site to unveil MSK Bergen, a sleek, modern, technology-filled 110,000-plus-square-foot clinical program located on Summit Avenue, mere minutes from the Garden State Parkway.
Peter T. Meinke will take the Tri-I TDI into the next phase of growth.
MSK Physician-in-Chief José Baselga, MD, PhD
The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, locally advanced or metastatic breast cancer. Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented this data, from the SANDPIPER trial, in a press conference at the annual meeting of the American Society of Clinical Oncology. This combination of a mutant-selective PI3K inhibitor and a selective estrogen receptor degrader halted the growth of advanced breast cancer for two months longer than hormone therapy alone and decreased the chance of cancer worsening by 30 percent.